Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Naratriptan.

H Massiou1

  • 1Hĵpital Lariboisière, Paris, France. hmassiou@club-internet.fr

Current Medical Research and Opinion
|December 5, 2002
PubMed
Summary
This summary is machine-generated.

Naratriptan effectively relieves migraine symptoms like headache, nausea, and light sensitivity, offering consistent relief with a low recurrence rate and a favorable safety profile compared to placebo.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Should women suffering from migraine with aura be screened for biological thrombophilia?: results from a cross-sectional French study.

Thrombosis research·2014
Same author

Pure psychiatric presentation of Fragile X-associated tremor/ataxia syndrome.

European journal of neurology·2013
Same author

[Treatment of migraine: present and future].

La Revue de medecine interne·2010
Same author

The GRIM2005 study of migraine consultation in France. III: Psychological features of subjects with migraine.

Cephalalgia : an international journal of headache·2009
Same author

Evaluation and registration of adverse events in clinical drug trials in migraine.

Cephalalgia : an international journal of headache·2008
Same author

The GRIM2005 study of migraine consultation in France II. Psychological factors associated with treatment response to acute headache therapy and satisfaction in migraine.

Cephalalgia : an international journal of headache·2007
Same journal

Treatment patterns among pediatric and adult patients with ulcerative colitis in the United States: a retrospective cohort study.

Current medical research and opinion·2026
Same journal

Multidrug-resistant <i>Pseudomonas aeruginosa</i> in Jordan: epidemiology, trends, determinants, and clinical outcomes.

Current medical research and opinion·2026
Same journal

RSV disease and vaccination knowledge, attitudes, and practices among US adults: a 2024-2025 RSV season survey.

Current medical research and opinion·2026
Same journal

Clinical and healthcare resource utilization outcomes following revision knee arthroplasty with and without a gradually reducing radius revision knee system.

Current medical research and opinion·2026
Same journal

Medication adherence measurement methods and their reported relationship with medication safety outcomes: a scoping review.

Current medical research and opinion·2026
Same journal

BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia.

Current medical research and opinion·2026
See all related articles

Area of Science:

  • Pharmacology
  • Neurology
  • Vascular Biology

Background:

  • Naratriptan is a selective serotonin 5-HT(1B/1D) receptor agonist.
  • It exhibits high affinity for 5-HT(1B), 5-HT(1D), and 5-HT(1F) receptor subtypes.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of naratriptan for migraine treatment.
  • To compare naratriptan's effects with placebo and sumatriptan.

Main Methods:

  • Clinical trials assessing headache relief, pain freedom, and associated symptoms (nausea, photophobia, phonophobia).
  • Evaluation of within-patient consistency, recurrence rates, and side-effect profiles.
  • Pharmacological studies on isolated cerebral arteries and cranial neurogenic inflammation models.

Related Experiment Videos

Main Results:

  • Naratriptan (2.5 mg) demonstrated significant superiority over placebo in headache relief and pain freedom at 2 and 4 hours.
  • It effectively reduced nausea, photophobia, and phonophobia.
  • Naratriptan showed a low recurrence rate and was well-tolerated, with side effects comparable to placebo at the 25 mg dose.

Conclusions:

  • Naratriptan is an effective treatment for acute migraine attacks.
  • It offers a favorable tolerability profile and low recurrence rate, making it a valuable therapeutic option.
  • Compared to sumatriptan, naratriptan has a slower onset but better tolerability and lower recurrence.